Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónWO2000012147 A1
Tipo de publicaciónSolicitud
Número de solicitudPCT/US1999/019697
Fecha de publicación9 Mar 2000
Fecha de presentación31 Ago 1999
Fecha de prioridad2 Sep 1998
También publicado comoCA2338788A1, EP1119379A1
Número de publicaciónPCT/1999/19697, PCT/US/1999/019697, PCT/US/1999/19697, PCT/US/99/019697, PCT/US/99/19697, PCT/US1999/019697, PCT/US1999/19697, PCT/US1999019697, PCT/US199919697, PCT/US99/019697, PCT/US99/19697, PCT/US99019697, PCT/US9919697, WO 0012147 A1, WO 0012147A1, WO 2000/012147 A1, WO 2000012147 A1, WO 2000012147A1, WO-A1-0012147, WO-A1-2000012147, WO0012147 A1, WO0012147A1, WO2000/012147A1, WO2000012147 A1, WO2000012147A1
InventoresDachuan Yang, Lixiao Wang
SolicitanteScimed Life Systems, Inc.
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos:  Patentscope, Espacenet
Drug delivery device for stent
WO 2000012147 A1
Resumen
A device adapted for mounting on a stent, the device comprising a sheath being made of polymeric material that includes drugs such as pharmaceutical agent(s) or radioactive agent(s) for delivery to an implant site. The sheath includes a main body of a generally tubular shape, and may include mounting means for attaching same to the stent. The device may have a slit therein, and may comprise a helical coil, a cylinder or any other suitable shape or design which fits a particular stent. The sheath may include a coating or coatings thereon containing drugs, surgical adhesives or a combination thereof.
Reclamaciones  (El texto procesado por OCR puede contener errores)
WHAT IS CLAIMED IS: What is claimed is:
I . An implantable intraluminal apparatus comprising in combination: an expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion, an exterior surface and an interior flow passage defined therethrough; and a sheath constructed and arranged for mounting on the stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby. 2. The apparatus of claim 1 wherein the sheath comprises polyurethane.
3. The apparatus of claim 1 wherein the sheath comprises polytetrafluoroethylene.
4. The apparatus of claim 1 wherein the sheath comprises a gel-like material.
5. The apparatus of claim 1 wherein the sheath comprises a cellulose polymer.
6. The apparatus of claim 1 wherein the sheath comprises a biodegradable polymer. 7. The apparatus of claim 1 wherein the sheath comprises poly(N-vinyl-2-pyrollidone).
8. The apparatus of claim 1 wherein the sheath comprises polyethylene oxide.
9. The apparatus of claim 1 wherein the drug is selected from the group consisting of pharmaceutical agents, radioactive agents, bioactive agents and combinations thereof.
I I . The apparatus of claim 1 wherein the drug is selected from the group consisting of TAXOL, vascular endothelial growth factor, heparin, 5-fluorouracil, beta-estradiol, tranilast, trapidil, probucol, and angiopeptin.
12. The apparatus of claim 1 wherein the sheath is cylindrical.
13. The apparatus of claim 1 wherein the sheath further comprises a proximal end, a distal end and a slit extending from the proximal end to the distal end. 14. The apparatus of claim 13 wherein the slit is a longitudinal slit.
15. The apparatus of claim 13 wherein the slit is helical.
16. The apparatus of claim 1 wherein the sheath is a helical coil.
17. The apparatus of claim 1 wherein the sheath comprises a plurality of layers.
18. The apparatus of claim 17 wherein the plurality of layers is comprised of the same material.
19. The apparatus of claim 17 wherein the plurality of layers is comprised of different materials.
20. The apparatus of claim 17 wherein at least one of the layers includes a drug.
21. The apparatus of claim 1 wherein the sheath further comprises an inner surface, an outer surface, and a coating covering at least a portion of the outer surface thereof. 22. The apparatus of claim 21 wherein the coating comprises a biocompatible polymer.
23. The apparatus of claim 21 wherein the coating comprises polyethylene oxide.
24. The apparatus of claim 21 wherein the coating comprises polyurethane.
25. The apparatus of claim 21 wherein the coating comprises a gel-like material.
26. The apparatus of claim 21 wherein the drug is carried by the coating. 27. The apparatus of claim 21 wherein the coating includes a bioadhesive.
28. The apparatus of claim 27 wherein the bioadhesive is selected from the group consisting of cyanoacrylate, fibrin glue, gelatin-resorcinol-formol glue.
29. The apparatus of claim 21 wherein the coating comprises a plurality of layers.
30. The apparatus of claim 29 wherein the plurality of layers is comprised of the same coating material.
31. The apparatus of claim 29 wherein the plurality of layers is comprised of different coating materials.
32. The apparatus of claim 29 wherein at least one of the layers includes a drug.
33. An implantable intraluminal apparatus comprising: a sheath constructed and arranged for mounting on a stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
34. A sheath constructed and arranged for mounting on a stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
35. A sheath for an implantable intraluminal apparatus for delivery of a stent, the sheath constructed and arranged for mounting on a stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
36. A sheath for being delivery into the body with a stent, the sheath constructed and arranged for mounting on a stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
37. A drug delivery sheath for delivering drugs within the body, the sheath constructed and arranged for being associated with a stent for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
38. A sheath constructed and arranged for being introduced within the body for delivery of drugs to an implanted site, said sheath comprising a biocompatible polymeric material and a drug carried thereby.
Descripción  (El texto procesado por OCR puede contener errores)

DRUG DELIVERYDEVICE FORSTENT

BACKGROUND OF THE INVENTION This invention relates to a device for providing mechanical support to a vessel lumen of a living being. This invention also relates to the delivery of materials which prevent restenosis of a vessel.

A variety of medical situations requires the use of a mechanism to expand and support a constricted vessel and to maintain an open passageway through the vessel. A few examples of such situations following angioplasty include holding a dissection in place, preventing closure during spasm, and preventing acute closure due to thrombosis. In these situations, devices, commonly known as stents, are useful to maintain the patency of body passages, to prevent stenosis of a dilated vessel, to eliminate the danger of occlusion caused by "flaps" resulting from intimal tears that may be associated with angioplasty, or to hold two ends of a vessel in place.

Stents are generally tubular in configuration, open ended and are expandable between a generally unexpanded insertion diameter and an expanded implantation diameter. Stents are commonly placed or implanted by a mechanical transluminal procedure.

Specifically, U.S. Patent 4,733,665 to Palmaz discloses a number of stent configurations for implantation with the aid of a catheter. U.S. Patent 5,019,090 to Pinchuk discloses a generally cylindrical stent and technique for implanting it using a deflated balloon catheter to position the stent. U.S. Patents 4,503,569 to Dotter and 4,512,338 to Balko et al. disclose a spring stent and a shape memory alloy stent. There are also self- expanding stents such as those described in U.S. Patents 4,732,152 to Wallsten et al. and 4,848,343 to Wallsten et al. All of these patents are hereby incorporated by reference.

Stents have been made using materials of varied composition and conformation. McGreevy et al U.S. Patents 4,690,684 and 4,770,176 describe a meltable stent that is inserted into the interior of the ends of a blood vessel during anastomosis. Anastomosis refers to the surgical or physical connection of two tubular structures, such as veins or arteries. The stent is made of blood plasma, which is biologically compatible with the living being and which melts rapidly in response to heat. Fischell et al., in U.S. Patent 4,768,507 describe an intravascular stent which is an unrestrained coil spring having an outside diameter of 2 to 12 millimeters and a length of 5 to 25 millimeters. The materials of construction are stainless steel, and a titanium alloy. Decreased thrombogenicity is achievable by coating the outside of the coil with a non-thrombogenic material such as ULTI carbon.

Leeven et al., in U.S. Patent 4,820,298 describe a stent having a flexible tubular body made from a thermal plastic to the form of a helix. Polyester and polycarbonate copolymers are selected as particularly desirable materials.

Wolff et al., in U.S. Patent 4,830,003 describe a stent made from wires formed into a cylinder. The wires are made of a biocompatible metal. Biocompatible metals include 300 series stainless steels such as 316 LSS, as well as platinum and platinum-iridium alloys, cobalt-chromium alloys such as MP35N, and unalloyed titanium. Wiktor in U.S. Patent 4,886,062 describes a stent made from low memory metal such as a copper alloy, titanium, or gold. The stent is preformed into a two-dimensional zig-zag form creating a flat expandable band.

Gianturco in U.S. Patent 4,907,336 describes a wire stent having a cylindrical shape that results from an expandable serpentine configuration. Malleable materials of construction are preferably included from the group of annealed stainless steels, tungsten and platinum.

Goldberg et al, in Canadian Application 2,025,626, describes a bio-degradable infusion stent used to treat ureteral obstructions. The application describes an extruded material of construction made of epsilon-caprolactone (15-25% w/w of terpolymer composition); glycoside (5-50% w/w) and L(-)lactide (45-85% w/w). This material was described as having a minimum tensile strength of at least 500 pounds per square inch, preferably 650 psi; elongation of greater than 10%, preferably greater than 100%; and Shore A hardness equal to 50-100%, preferably 75-95%. The Goldberg et al patent application describes a method for incorporating radiopaque materials such as barium sulfate into the polymer in amounts ranging from 5-30%. The mechanism of biodegradation is described as hydrolysis resulting in degradable products excreted in urine or reabsorbed into tissues. The duration of functional life of the stent is estimated at about 3-7 weeks.

Wilcoff in U.S. Patent 4,990,155 describes a plastic stent having an inherently expandable coil conformation. The "inherency" results from an elastic memory conferred by electron beam radiation imparting cross-linkages that provide an inherent tendency to return to a given diameter after any distortion. Materials of construction include high density polyethylene. Optionally, this material is compounded with an anti-coagulant and/or an x-ray opaque material such as bismuth-sub-carbonate.

Sigwart, Canadian Patent Application 2,008,312, describes a stent made from a malleable flat sheet having a reticulated pattern. The reticulated pattern includes non-deformable squares or diamonds. The stent is made by rolling the sheet and locking the sheet into a spiral having a small diameter. The sheet is locked into a spiral by a tie interwoven into the reticulated pattern. Once inserted into the lumen of a vessel, the spiral is expanded and held in place by flaps integrated into the outer body of the stent.

Shockley et al., in U.S. Patent 4,994,033, describe a drug delivery dilatation catheter having three flexible, plastic tubes concentrically arranged relative to each other. The outermost sleeve of this catheter contains microholes for drug delivery. These microholes are made with a laser beam. Drugs that can be delivered by this system include aspirin, persantin, heparin, and prostaglandins. Drugs are delivered when externally applied pressure causes the innermost sleeve to balloon out. The drug is then forced through the microholes to spray and to treat a lesion.

There are also stents which deliver agents or drugs to blood passing through the vein or artery that are generally beneficial to the recipient. In addition, stents can deliver drugs or biologically active agents at a controlled rate to blood passing through the vessel lumen as well as to the vessel wall. Silvestrini in U.S. Patent 5,234,456 describes a hydrophilic stent comprising a wall structure where at least a portion thereof is a hollow wall in which a hydrophilic material for drug delivery is placed. U.S. Patent 5,443,458 to Eury et al., is directed to a multilayer laminated resorbable stent having a structural layer and additional layers stated to release drugs at predictable rates. Froix in U.S. 5,258,020 describes a self-restrained stent with an elastic memory, the stent optionally being formulated to provide for drug administration.

It is known that when stents are expanded to their implantation diameter the ends of the stent may press into the vessel or cavity walls, especially the distal end of the stent. The sharp or pointed edges and ends of some stents may then damage the walls. Once damage has occurred, there is a likelihood that restenosis will occur at these points where the stents ends and edges have penetrated or pressed against the walls.

Restenosis occurs in a number of cases where a stent has been used. Tearing of the wall of the passage or injury of the endothelial cell layer are possible causes of the restenosis. The torn wall or flap usually is the source of the blockage. When the wall is torn, a flap of tissue is created, which falls into the passage and blocks it. It is then necessary to perform another procedure to remove the blockage and generally, another stent is needed to open the vessel or other passage. Metal stents are known to cause 10% to 30% or more restenosis in application.

Therefore, it desirable to utilize a stent which reduces the chances of a damaged vessel wall or body passage which leads to further problems and further necessary procedures. However, current stents are not designed to reduce the occurrence of cutting of vascular passages or the like. U.S. Patent Application No. 09/072,944, incorporated herein by reference, is directed to a stent having at least one smooth end. The stent may include a coating or coatings on one or both end portions to provide a smooth finish to reduce possible damage to body passages when the stent is deployed and delivered. The stent may also contain drugs or surgical adhesives or a combination thereof in or on the coated portion of the stent. The stent may also be of the type where the materials of the stent may be treated to have a smooth flexible end or ends. The stent may also be of a configuration such that at least one end is more flexible than the middle portion of the stent.

U.S. Patent Application No. 08/874,190, incorporated herein by reference, discloses a polymeric layered stent characterized in that it includes a multilayered material comprised of an inner polymer layer and an overlying outer polymer layer. The self- expanding or balloon expandable stent disclosed therein is provided in two forms, one including inner and outer polymeric layers, and another comprising a prior art stent provided with polymeric layer(s) coated thereon.

While U.S. Applications 09/072,944 and 08/874,190 are directed in part to this need, there still exists a need for a means for delivering drugs or biologically active agents which assist in preventing restenosis, which can be easily mounted on an existing stent prior to implantation.

SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention is to provide a polymeric device adapted for mounting onto a stent. The device of polymeric material may comprise a sheath or sleeve that is cylindrical, a helical coil, or any other suitable shape or design which fits a particular stent. The stent may be metallic or non-metallic, or alternatively a combination of metallic and non-metallic materials. An example of a preferred stent for use with the device of the present invention is the NIR stent, set forth in U.S. Patent 5,733,303, incorporated herein by reference. In addition, the device may be used with a stent as set forth in U.S. Application No. 08/874,190, incorporated herein by reference. The device may be of a biocompatible material and may be either biodegradable or non-biodegradable. The device may also be water soluble. It may contain pharmaceutical agent(s) or radioactive agent(s). The device is adapted for mounting onto a stent prior to use for insertion into a lumen of a vessel in a living being, and may be expanded with the stent. The device is optionally biodegradable, and may be made from at least one biodegradable material that is also biocompatible and includes a drug which is released into the lumen of the vessel at a rate controlled by the rate of degradation of the biodegradable material.

Generally, any prior art stent may be improved by providing it with the device of the present invention. The use of this inventive device with an existing stent provides a simple method for reducing restenosis.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an enlarged perspective view of a device according to the present invention;

Figures 2a and 2b are perspective views of an alternative embodiment of the device of the present invention;

Figure 3 is a perspective view of an alternaive embodiment of the device of the present invention;

Figure 4 is a perspective view of an alternative embodiment of the device of the present invention; Figure 5 is a cross section taken along the line 5-5 of Figure 4;

Figure 6 is a perspective view of an alternative embodiment of a device according to the present invention;

Figure 7 is a cross section taken along line 7-7 of Figure 6; Figure 8 is a perspective view of an alternative embodiment of a device according to the present invention;

Figure 9 is a fragmentary perspective view of the sheath as shown in Figure 8 mounted on a stent; Figure 10 is a fragementary perspective view as in Figure 9 showing the stent and sheath after expansion of the stent; and

Figure 11 is a fragementary side elevational view with parts broken away of the stent with the sheath of the present invention in an implanted site. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is a polymeric device adapted for mounting onto a stent. Referring to Figures 1-4, the device may be a sheath as shown generally at 10. Sheath 10 has a proximal end 12, a distal end 14, an interior surface 16 and an exterior surface 18. As shown at Figures 2a, 2b and 3, sheath 10 may have a slit 15 therein extending from proximal end 12 to distal end 14. As shown at Figure 2a, slit 15 is a longitudinal slit 15 a. Figure 2b shows the same sheath in a compressed configuration it may take on prior to being mounted on a stent. Alternatively, slit 15 may be a helical slit 15b, as shown at Figure 3. Referring to Figure 4, sheath 10 may be provided with perforations 17 therethrough. In addition, sheath 10 may comprise multiple layers, for example as shown in cross section at Figure 5 having two layers. Alternatively, sheath 10 may comprise a plurality of layers. Referring to Figures 6-7, sheath 10 may be shaped like a spring, which spring may optionally be formed from a tubular member, as exemplified by the cross section at Figure 7.

Referring now to Figures 8-10, a sheath comprising a helical coil is shown. Figure 8 is a perspective view of sheath 10. At Figure 9, a partial section view of sheath 10 mounted on a stent 20 is shown prior to implantation and expansion. Stent 20 includes a generally tubular main body 21, a proximal end 22 (not shown in this view), a distal end 24 (not shown in this view), an interior surface 26 and an exterior surface 28. Prior to implantation, sheath 10 is mounted on stent 20 such that the exterior surface 28 of main body 21 faces the interior surface 16 of sheath 10.

In use, sheath 10 is placed on the outer surface 24 of stent 20 prior to implantation thereof. Sheath 10 may be held on stent 20 by any suitable means including compressive force, glue, a protective sheath, socks or the like.

The compressive force may be supplied by the sheath itself, the stent or both. The glue is preferably a biocompatible glue such as fibrin, collagen or gelatin. Any appropriate bioadhesive may be used. For example, the following bioadhesives may be used singly or in combination: cyanoacrylate: ethyl cyanoacrylate, butyl cyanoacrylate, octyl cyanoacrylate, hexyl cyanoacrylate; fibrin glue: fibrinogen/thrombin Factor Xlll/calcium as catalyst gelatin-resorcinol-formol (GRF) glue: formed from gelatin, resorcinol and water in the presence of formaldehyde, glutaraldehyde and heat (45°C); mussel adhesive protein, prolamine gel and transforming growth factor beta(TGF-B); polyacrylic acid, modified hydrocellulose, hydroxypropylmethyl cellulose, hydroxypropylcellulose, carboxymethyl cellulose, sodium alginate, gelatin, pectin, polyvinylpylindone, polyethylene glycol, aldehyde relative multifunctional chemicals, polyallylsaccharose, and polypeptides.

A protective sheath may also be used to secure sheath 10 to stent 20. A sheath or sheaths as disclosed in U.S. Application Nos. 08/812,351 and 09/034,434, incorporated herein by reference, may be used, but would be retained over sheath 10 in use.

At least one sock covering a portion of sheath 10 over stent 20 may also be used. Such a retaining device as is disclosed in U.S. Application No. 08/917,027, incorporated herein by reference, may be used. One use of the sheath of the present invention is to allow physicians to add it to any stent and delivery system they already have. The sheath may therefore be provided as a stand alone device.

Stent 20 with sheath 10 mounted thereto is positioned at the inner surface wall 34 of the vessel 32 by radially compressing the stent with sheath to a tubular diameter less than the diameter of the vessel 32 and moving stent 20 to a desired site within vessel 32. Stent 20 is implanted in the known manner depending upon its type. For example, a self expanding stent would be released from compression so that the stent can radially spring out to abut against the inner surface wall 34 of vessel 32. The stent may also be of the balloon expandable type. In any case, sheath 10 is adapted for mounting onto stent 20 and expansion therewith. Figure 10 shows sheath 10 after expansion of stent 20.

At Figure 11, sheath 10 and stent 20 are shown in an implanted site, in the lumen 30 of a tubular vessel 32 in a body. Upon implantation, the exterior surface 18 of sheath 10 faces an inner surface wall 34 of the vessel 32. Stent 20 provides mechanical support to tubular vessel 32 in a living being. The stent strengthens the area of vessel 32 in which it is implanted. Sheath 10 releases a pharmaceutical agent or radioactive agent into lumen 30 of tubular vessel 32. The rate of release may vary. The present invention may be used with any stent. Such a stent may range from 1 millimeter in diameter to 50 millimeters in diameter and from 1 millimeter in length to 50 millimeters in length. The size of the stent is dictated by the lumen of the vessel to which the stent is placed. Tubular main body 21 suitably has a length of up to approximately 5 centimeters. Sheath 10 may be of any size suitable for use with a stent being implanted.

Many suitable materials may be used to form the sheath 10 of the present invention. For example, hydrophilic polymers, copolymers (block or graft) or their cross- linked versions (e.g. hydrogels), may be used, the polymers including poly(hydroxyethyl methacrylate) and derivatives; poly(vinyl alcohol); polyethylene oxide; poly ropylene oxide); polyacrylamides; polyacrylic acid; polymethacrylic acid; poly(N-vinyl-2- pyrollidone); hydrophilic polyurethanes; poly(amino acid); water soluble cellulosic polymers (sodium carboxymethyl cellulose, hydroxy ethyl cellulose, for example); collagens; carrageenan; alginate; starch; dextrin; and gelatins.

The device of the present invention may be made of biodegradable polymers including poly(lactide); poly(glycolide); polydioxanone(PDS); polycaprolactone; polyhydroxybutyrate(PHBT); poly(phosphazene); poly(phosphate ester); poly(lactide-co- glycolide); poly(glycolide-co-trimethylene carbonate); poly(glycolide-co-caprolactone); polyanhydrides; collagen or other connective proteins or natural materials, hyaluronic acid, adhesive proteins, co-polymers of these materials as well as composites or combinations thereof and combinations of other biodegradable polymers.

In addition, the device of the present invention may be made of biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. The device may also include bioactive agents which permit endothelial cells to grow on the device and the stent. It is believed that the endothelial cell growth will encapsulate particles of the stent during biodegradation that would otherwise come loose and form emboli in the blood stream. Suitable biodegradable materials for the device of the present invention include polylactic acid, polyglycolic acid, collagen or other connective proteins or natural materials, polycaprolactone, hyaluronic acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof, and combinations of other biodegradable polymers. Biodegradable glass or bioactive glass is also a suitable biodegradable material for use in the present invention. Preferably the materials have been accepted by the U.S. Food and Drug Administration.

One advantage of using a variety of biodegradable materials within the sheath is control of degradation. Biodegradable materials degrade at different rates, ranging from days or weeks to several years. Consequently, the presence of different biodegradable materials in the stent permits the sheath to degrade in a predictable manner. The device may further be coated with a biodegradable film layer.

Where sheath 10 is of a biodegradable material, the rate of release of the pharmaceutical agent or radioactive agent will be controlled by the rate of degradation of the biodegradable materials.

Further, the device of the present invention may be made of nonbiodegradable biocompatible materials such as polytetrafluoroethylene(PTFE); polyurethanes; polyamides; polyesters; polyethers; polyketones; polyether ester elastomers; polyether amide elastomers; polyacrylate-based elastomers; polyethylene; and polypropylene.

These lists are exemplary only. Any appropriate material may be used.

The sheath of the present invention includes pharmaceutical agent(s) and/or radioactive agent(s) or other biologically active materials. Where the sheath is biodegradable, these drugs, pharmaceutical agents, radioactive agents or biologically active materials are contained within the biodegradable materials of which the stent is composed. As the sheath biodegrades, drugs are released into the surrounding tissue or to the bloodstream. Thus, the rate of drug release is controlled by the rate of degradation of the biodegradable materials. A material that degrades rapidly will release the drug faster than a material that degrades slowly. Drugs are incorporated into the biodegradable sheath using techniques known in the art. The techniques include simple mixing or solubilizing with polymer solutions, dispersing into the biodegradable polymer during the formation of the sheath, or coating onto an already formed sheath.

Where the sheath has a film added thereto, drugs can be incorporated into the film by methods such as melting or solvation. Alternatively, biologically active agents are incorporated into the film layer by entrapment between such layer and the surface of biodegradable material sandwiched together, thereby further promoting release of the drugs or agents in a controllable manner.

The drugs or other biologically active materials incorporated into the sheath of the present invention perform a variety of functions. The functions include but are not limited to an anti-clotting or anti-platelet function and preventing smooth muscle cell growth on the inner surface of the vessel to reduce the chance of in-stent restenosis. The drugs include but are not limited to drugs that inhibit or control the formation of thrombus or thrombolytics such as heparin or heparin fragments, aspirin, coumadin, tissue plasminogen activator (TPA), urokinase, hirudin, and streptokinase, antiproliferatives (methotrexate, cisplatin, 5-fluorouracil, Taxol, Adriamycin, and the like) antioxidants (ascorbic acid, carotene, B, vitamin E, and the like), antimetabolites, thromboxane inhibitors, non-steroidal and steroidal antiinflammatory drugs, Beta and Calcium channel blockers, genetic materials including DNA and RNA fragments, and complete expression genes, carbohydrates, and proteins including but not limited to antibodies (monoclonal and polyclonal) lymphokines and growth factors, prostaglandins, and leukotrienes. The sheath material may also incorporate bioactive materials such as fibronectin, laminin, elastin, collagen, and intergrins. Fibronectin, for example, promotes adherence of the sheath to the tissue of the vessel 32.

In one specific example of a biodegradable material incorporating drugs, a poly-L-lactide having an intrinsic viscosity of 2.3 dl g is used to form monofilament fibers using a spin or melt spinning process. Five percent aspirin or 5% heparin was incorporated into the melt of the poly-L-lactide prior to fiber formation. The fibers formed had a diameter of approximately 0.5 millimeters. The monofilaments were then stretched under temperatures ranging from 50° C to 200° C to orient the fiber. The temperature employed depends upon the kind of material used to make the fiber. The final diameter of the oriented fiber falls within a range of 0.1 to 0.3 millimeters. Similar processing was used to incorporate 5% aspirin or 5% heparin into poly-L-lactide and polyglycolide. The device of the present invention may also include bioadhesives to be delivered to the site where the stent is needed. It is known that bioadhesives can be used to repair tissue walls. It is therefore desirable to utilize a polymer to deliver a bioadhesive to the stent implantation location. In this manner, a potential problem could be averted by the presence of the bioadhesive in the case of a tear or dissection.

Just as the use of a variety of biodegradable materials facilitates a controlled degradation of a biodegradable sheath according to the present invention, so similarly does the incorporation of a variety of drugs into the biodegradable materials facilitate control of drug release to perform a variety of functions. For instance, drugs released from the outer surface as the outer surface degrades facilitate adherence of the sheath to the inner surface wall 34 of the vessel 32. Drugs released from fibers perform a variety of functions, ranging from promoting cell growth to altering the blood clotting mechanisms, depending upon what drug released. In one embodiment, drugs released from the sheath as it degrades may temper platelet function in blood flowing through lumen . The device of the present invention may also be used as a drug delivery system to prevent restenosis or for other treatment. The drugs may include radioactive materials to irradiate and prohibit smooth muscle cell growth. Angioplasty and stent deployment may cause injury of the endothelial cell layer of blood vessels, causing smooth muscle cell proliferation, leading to restenosis. By accelerated endothelialization on the inner wall surface of vessels will prevent or prohibit the smooth muscle growth. To stimulate endothelialization without provoking smooth muscle cell proliferation, specific growth factors may be included and delivered. Growth factors include vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), insulin growth factor-1 (IGF-1), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), etc. All such materials are referred to herein generally as "drugs" or therapeutics.

These drugs may be dispersed in the matrix of the polymeric material.

For carrying drugs, a gel-like material may be used. The sleeve may be comprised of such a material, or it may be applied over the sleeve as a coating. There are several ways to apply drugs to such materials. The first way is to mix the drug with the materials, then form a sleeve therefrom. Alternatively the mixture may coated onto a sleeve. The gel-like materials can be cast as film or sheet with drug together, then formed into a sleeve or laminated to a sleeve. Another way is to form a sleeve from a gel-like material without a drug, or to coat or laminate a polymeric sleeve with a gel-like material without the drug. The sleeve is made, and then sterilized. Due to the gel-like nature, the sleeve can then be inserted into a drug solution. The drug will be absorbed into/onto the gel. The resulting drug-carrying sleeve can then be mounted to a stent and delivered into the body. The drug will then be released.

In one embodiment of the invention, the sleeve may be made of polyethylene oxide containing Taxol or coated with such a material. Other materials that may be used are copolymers such as PGA/PLA, PEO/PLA or the like containing a drug such as Taxol or heparin.

Preferred gel- like materials for use as a drug delivery sleeve or coating for a stent when drug delivery is desired are polyethylene oxide, polyvinyl pyrollidone, polyacrylates, and their blends or copolymers or lightly cross linked forms. Polyethylene glycol block copolymer with polylactides or other polyesters are examples. Hydrophilic polyurethane, poly(maleic anhydride-alt-ethylene) and their derivatives are examples. Other materials are polysaccharides and their derivatives. There are also sodium alginate, karaya gum, gelatin, guar gum, agar, algin carrageenans, pectin, locust bean gums, xanthan, starch-based gums, hydroxy alkyl and ethyl ethers of cellulose, sodium carboxymethyl cellulose. Some of the materials will be heated, then cooled, then a gel is formed. Some of the above are food gels. Some of them are bioadhesives.

Any drugs may be used, singly or in combination. For example, the drugs can be an anticoagulant, e.g. aspirin, ticlopidine, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, antibodies, urokinase, prostaglandin inhibitors, platelet inhibitors, or antiplatelet peptide. The drug can be an inhibitor of vascular cell growth, DNA, RNA, cholesterol-lowering agents, vasodilating agents. The drug can be any drug such as Taxol, 5-fluorouracil, Beta-Estradiol, Tranilast, Trapidil, Probucol, Angiopeptin or any combination of them.

Since there are many drugs and many polymers, the sleeve can have multiple layers of different polymers with the same or different drugs. For example, the sleeve can have two layers of the same polymer with one layer with drug and another layer without drugs. The sleeve may have two layers of the same polymer with two different drugs as another example. In particular, various combinations of a cycling sinase inhibitor identified as p21 and the vascular endothelial growth factor identified as VEGF, an endothelial nitrogen, may preferably be included in and dispensed from the sleeve or coating provided thereon. Incorporation of drugs and growth factors into the sleeve material or coating thereof can also be performed by several other methods, including the solvent method, melting method, soaking method and spraying method. If both polymer and drug have a cosolvent, a solution case will be an easy way to provide the polymer matrix loaded with the drug or growth factor. If the polymer can be melted at low temperature and the drug or growth factor tolerates heating, a melting method can be used to mix the drug or growth factor into the polymer matrix. Also, a polymer-drug solution or suspension solution can be used for coating to provide a layer containing the drug or growth factor.

In another embodiment of the invention the sleeve may be coated with a film of bioadhesive. Bioadhesives glue the tissue together. Using a bioadhesive for the coating serves two purposes. If a tear has occurred prior to or during delivery of the stent on which the sleeve is mounted, the tissue can be repaired. In this manner, blood flow will be maintained in a vessel, for example. The bioadhesive may or may not also have drugs loaded for delivery. Dissection, cutting or tearing occurs in some stent delivery and PTCA procedures. Bioadhesives or surgical adhesives may be used to repair the passage wall. However, these tears or cuts are not necessarily discovered immediately. In those cases, a further medical procedure must be undertaken to repair the wall. The need for such an additional medical procedure may be eliminated where a bioadhesive is included as a coating on the sleeve mounted to the stent which is deployed in place, as the bioadhesive will repair damage to the vessel wall. The bioadhesive is chosen as the coating for the sleeve, or is used in addition to a coating on the sleeve and is applied in a known manner to the sleeve. The end or edge, side, outside and/or inside of the sleeve may utilize the bioadhesive.

Any appropriate bioadhesive may be used. For example, the following bioadhesives may be used singly or in combination: cyanoacrylate: ethyl cyanoacrylate, butyl cyanoacrylate, octyl cyanoacrylate, hexyl cyanoacrylate; fibrin glue: fibrinogen/thrombin/Factor Xlll/calcium as catalyst gelatin-resorcinol-formol (GRF) glue: formed from gelatin, resorcinol and water in the presence of formaldehyde, glutaraldehyde and heat (45 °C); mussel adhesive protein, prolamine gel and transforming growth factor beta(TGF-B); polyacrylic acid, modified hydrocellulose, hydroxypropylmethyl cellulose, hydroxypropylcellulose, carboxymethyl cellulose, sodium alginate, gelatin, pectin, polyvinylpylindone, polyethylene glycol, aldehyde relative multifunctional chemicals, polyallylsaccharose, and polypeptides.

Suitable materials for the device of the present invention and suitable drugs to be delivered thereby are also set forth in U.S. Application No. 08/874,190.

Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

The above Examples and disclosure are intended to be illustrative and not exhaustive. These examples and description will suggest many variations and alternatives to one of ordinary skill in this art. All these alternatives and variations are intended to be included within the scope of the attached claims. Those familiar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims attached hereto. F:\WPWORK\WEA\8471-APP.831

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
WO1993006792A1 *2 Oct 199215 Abr 1993Scimed Life Systems, Inc.Biodegradable drug delivery vascular stent
WO1995029647A2 *26 Abr 19959 Nov 1995Scimed Life Systems, Inc.Stent with collagen
WO1996025176A1 *15 Feb 199622 Ago 1996Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
WO1998036784A1 *20 Feb 199827 Ago 1998Cook IncorporatedCoated implantable medical device
EP0578998A1 *22 Jun 199319 Ene 1994Strecker, Ernst Peter, Dr.-med.Prof.Implantable percutaneous endoprosthesis
EP0604022A1 *24 Nov 199329 Jun 1994Advanced Cardiovascular Systems, Inc.Multilayered biodegradable stent and method for its manufacture
EP0712615A1 *16 Nov 199522 May 1996Advanced Cardiovascular Systems, Inc.Drug-loaded elastic membrane and method for delivery
EP0716836A1 *11 Dic 199519 Jun 1996Advanced Cardiovascular Systems, Inc.Polymer film for wrapping a stent structure
US45035693 Mar 198312 Mar 1985Dotter Charles TTransluminally placed expandable graft prosthesis
US451233825 Ene 198323 Abr 1985Balko Alexander BProcess for restoring patency to body vessels
US47321525 Dic 198522 Mar 1988Medinvent S.A.Device for implantation and a method of implantation in a vessel using such device
US47336657 Nov 198529 Mar 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US484834330 Oct 198718 Jul 1989Medinvent S.A.Device for transluminal implantation
US50190901 Sep 198828 May 1991Corvita CorporationRadially expandable endoprosthesis and the like
US5383928 *19 Ago 199324 Ene 1995Emory UniversityStent sheath for local drug delivery
US5578075 *1 Jun 199526 Nov 1996Michael Peck DaytonMinimally invasive bioactivated endoprosthesis for vessel repair
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
WO2001021157A2 *21 Sep 200029 Mar 2001Institut De Cardiologie De MontrealLocal delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury
WO2001021157A3 *21 Sep 200013 Dic 2001Baskaran ChandrasekarLocal delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury
WO2003030784A130 Jul 200217 Abr 2003Boston Scientific LimitedStent design with sheath attachment members
WO2003057077A1 *6 Dic 200217 Jul 2003Advanced Cardiovascular Systems, Inc.Hybrid stent
WO2004112655A1 *17 Jun 200429 Dic 2004Medtronic Vascular Inc.Superelastic coiled stent
WO2005112570A2 *4 May 20051 Dic 2005Medtronic Vascular, Inc.Drug-polymer coated stent
WO2005112570A3 *4 May 20054 May 2006Medtronic Vascular IncDrug-polymer coated stent
DE10107795B4 *13 Feb 200115 May 2014Berlex AgGefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze
DE10150995A1 *8 Oct 200110 Abr 2003Biotronik Mess & TherapiegImplant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time
DE102005007596A1 *18 Feb 200524 Ago 2006Breeze Medical, Inc., Boca RatonÜberzug, Herstellungsverfahren und Verfahren zum Aufbringen eines Überzuges auf ein medizinisches Instrument sowie medizinisches Instrument
EP1217963A1 *9 Jun 20003 Jul 2002C.R. Bard, Inc.Devices and methods for treating tissue
EP1217963A4 *9 Jun 200012 Dic 2007Bard Inc C RDevices and methods for treating tissue
EP1933936A2 *12 Oct 200625 Jun 2008Synthes GmbHDrug-impregnated encasement
EP1933936A4 *12 Oct 200612 May 2010Synthes GmbhDrug-impregnated encasement
US637938213 Mar 200030 Abr 2002Jun YangStent having cover with drug delivery capability
US644743919 Oct 200010 Sep 2002Sorin Biomedica Cardio S.P.A.Device for conveying radioactive agents on angioplasty stents, respective method and kit
US64513734 Ago 200017 Sep 2002Advanced Cardiovascular Systems, Inc.Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US64917203 Ago 200010 Dic 2002Sorin Biomedica S.P.A.Angioplasty stent adapted to counter restenosis respective kit and components
US650355628 Dic 20007 Ene 2003Advanced Cardiovascular Systems, Inc.Methods of forming a coating for a prosthesis
US650395421 Jul 20007 Ene 2003Advanced Cardiovascular Systems, Inc.Biocompatible carrier containing actinomycin D and a method of forming the same
US654077628 Dic 20001 Abr 2003Advanced Cardiovascular Systems, Inc.Sheath for a prosthesis and methods of forming the same
US65856326 Sep 20021 Jul 2003Sorin Biomedica Cardio S.P.A.Device for conveying radioactive agents on angioplasty stents, respective method and kit
US661308213 Mar 20002 Sep 2003Jun YangStent having cover with drug delivery capability
US661308428 Nov 20012 Sep 2003Jun YangStent having cover with drug delivery capability
US663830223 Dic 199728 Oct 2003Sorin Biomedica Cardio S.P.A.Stent for angioplasty and associated production process
US666388030 Nov 200116 Dic 2003Advanced Cardiovascular Systems, Inc.Permeabilizing reagents to increase drug delivery and a method of local delivery
US671284524 Abr 200130 Mar 2004Advanced Cardiovascular Systems, Inc.Coating for a stent and a method of forming the same
US671311923 Dic 199930 Mar 2004Advanced Cardiovascular Systems, Inc.Biocompatible coating for a prosthesis and a method of forming the same
US673376825 Jun 200211 May 2004Advanced Cardiovascular Systems, Inc.Composition for coating an implantable prosthesis
US674962617 Nov 200015 Jun 2004Advanced Cardiovascular Systems, Inc.Actinomycin D for the treatment of vascular disease
US675307127 Sep 200122 Jun 2004Advanced Cardiovascular Systems, Inc.Rate-reducing membrane for release of an agent
US675905428 Dic 20006 Jul 2004Advanced Cardiovascular Systems, Inc.Ethylene vinyl alcohol composition and coating
US678042430 Mar 200124 Ago 2004Charles David ClaudeControlled morphologies in polymer drug for release of drugs from polymer films
US679022828 Dic 200014 Sep 2004Advanced Cardiovascular Systems, Inc.Coating for implantable devices and a method of forming the same
US681824727 Abr 200116 Nov 2004Advanced Cardiovascular Systems, Inc.Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent
US682455922 Dic 200030 Nov 2004Advanced Cardiovascular Systems, Inc.Ethylene-carboxyl copolymers as drug delivery matrices
US683315331 Oct 200021 Dic 2004Advanced Cardiovascular Systems, Inc.Hemocompatible coatings on hydrophobic porous polymers
US68490892 Oct 20021 Feb 2005Biotronik Mess-Und Therapiegeraete Gmbh & Co Ingenieurbuero BerlinImplant with proliferation-inhibiting substance
US689046322 Abr 200210 May 2005Atrium Medical CorporationMethod for treating expandable polymer materials
US689696512 Nov 200224 May 2005Advanced Cardiovascular Systems, Inc.Rate limiting barriers for implantable devices
US690862416 Dic 200221 Jun 2005Advanced Cardiovascular Systems, Inc.Coating for implantable devices and a method of forming the same
US692392723 Mar 20042 Ago 2005Atrium Medical CorporationMethod for forming expandable polymers having drugs or agents included therewith
US701486124 Oct 200321 Mar 2006Advanced Cardiovascular Systems, Inc.Permeabilizing reagents to increase drug delivery and a method of local delivery
US702233420 Mar 20024 Abr 2006Advanced Cardiovascular Systems, Inc.Therapeutic composition and a method of coating implantable medical devices
US702237212 Nov 20024 Abr 2006Advanced Cardiovascular Systems, Inc.Compositions for coating implantable medical devices
US716940430 Jul 200330 Ene 2007Advanced Cardiovasular Systems, Inc.Biologically absorbable coatings for implantable devices and methods for fabricating the same
US71726246 Feb 20036 Feb 2007Boston Scientific Scimed, Inc.Medical device with magnetic resonance visibility enhancing structure
US717587318 Jul 200213 Feb 2007Advanced Cardiovascular Systems, Inc.Rate limiting barriers for implantable devices and methods for fabrication thereof
US717587430 Nov 200113 Feb 2007Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US720193517 Sep 200210 Abr 2007Advanced Cardiovascular Systems, Inc.Plasma-generated coatings for medical devices and methods for fabricating thereof
US72111509 Dic 20021 May 2007Advanced Cardiovascular Systems, Inc.Apparatus and method for coating and drying multiple stents
US722647323 May 20035 Jun 2007Brar Balbir STreatment of stenotic regions
US723257326 Sep 200219 Jun 2007Advanced Cardiovascular Systems, Inc.Stent coatings containing self-assembled monolayers
US725589126 Feb 200314 Ago 2007Advanced Cardiovascular Systems, Inc.Method for coating implantable medical devices
US72886094 Mar 200330 Oct 2007Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices based on poly (orthoesters)
US729432918 Jul 200213 Nov 2007Advanced Cardiovascular Systems, Inc.Poly(vinyl acetal) coatings for implantable medical devices
US736307420 Ago 200222 Abr 2008Advanced Cardiovascular Systems, Inc.Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same
US737810618 Dic 200627 May 2008Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices and methods for fabricating the same
US739931210 Oct 200115 Jul 2008Scimed Life Systems, Inc.Stent design with sheath attachment members
US740497930 Sep 200229 Jul 2008Advanced Cardiovascular Systems Inc.Spin coating apparatus and a method for coating implantable devices
US741374615 May 200719 Ago 2008Advanced Cardiovascular Systems, Inc.Stent coatings containing self-assembled monolayers
US743872220 Sep 200221 Oct 2008Advanced Cardiovascular Systems, Inc.Method for treatment of restenosis
US74680524 Jun 200723 Dic 2008Brar Balbir STreatment of stenotic regions
US747327322 Ene 20026 Ene 2009Medtronic Vascular, Inc.Stent assembly with therapeutic agent exterior banding
US74791577 Ago 200320 Ene 2009Boston Scientific Scimed, Inc.Stent designs which enable the visibility of the inside of the stent during MRI
US750412528 Dic 200117 Mar 2009Advanced Cardiovascular Systems, Inc.System and method for coating implantable devices
US753446422 Mar 200719 May 2009Advanced Cardiovascular Systems Inc.Apparatus and method for coating and drying multiple stents
US75362216 Mar 200819 May 2009Advanced Cardiovascular Systems, Inc.Coatings comprising self-assembled molecular structures
US757224515 Sep 200411 Ago 2009Atrium Medical CorporationApplication of a therapeutic substance to a tissue location using an expandable medical device
US758551612 Nov 20018 Sep 2009Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US758879421 Sep 200715 Sep 2009Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices based on poly (orthoesters)
US76048313 Jun 200820 Oct 2009Advanced Cardiovascular Systems Inc.Stent spin coating method
US76221462 Nov 200624 Nov 2009Advanced Cardiovascular Systems, Inc.Rate limiting barriers for implantable devices and methods for fabrication thereof
US764550426 Jun 200312 Ene 2010Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
US765169518 May 200126 Ene 2010Advanced Cardiovascular Systems, Inc.Medicated stents for the treatment of vascular disease
US766634229 Jun 200723 Feb 2010Abbott Cardiovascular Systems Inc.Method of manufacturing a stent from a polymer tube
US7674416 *22 Dic 20049 Mar 2010Advanced Cardiovascular Systems, Inc.Hybrid intravascular stent
US77045454 May 200527 Abr 2010Medtronic Vascular, Inc.Drug-polymer coated stent
US773253523 Mar 20058 Jun 2010Advanced Cardiovascular Systems, Inc.Coating for controlled release of drugs from implantable medical devices
US773978127 Mar 200722 Jun 2010Sorin Biomedica Cardio S.R.LProcess for producing a stent for angioplasty
US7740791 *30 Jun 200622 Jun 2010Advanced Cardiovascular Systems, Inc.Method of fabricating a stent with features by blow molding
US787528515 Jul 200325 Ene 2011Advanced Cardiovascular Systems, Inc.Medicated coatings for implantable medical devices having controlled rate of release
US79412126 Mar 200810 May 2011Advanced Cardiovascular Systems, Inc.Method of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure
US79453196 Mar 200817 May 2011Advanced Cardiovascular Systems, Inc.Methods of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure
US79460196 May 201024 May 2011Sorin Biomedica Cardio S.R.L.Process for producing a stent for angioplasty
US794701518 May 200724 May 2011Atrium Medical CorporationApplication of a therapeutic substance to a tissue location using an expandable medical device
US80019258 Mar 201023 Ago 2011Medtronic Vascular, Inc.Drug-polymer coated stent
US80031235 May 200823 Ago 2011Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices and methods for fabricating the same
US80078555 Jul 200730 Ago 2011Advanced Cardiovascular Systems, Inc.Method for coating implantable medical devices
US800785830 Ene 200930 Ago 2011Advanced Cardiovascular Systems, Inc.System and method for coating implantable devices
US801240215 Abr 20096 Sep 2011Abbott Cardiovascular Systems Inc.Tube expansion process for semicrystalline polymers to maximize fracture toughness
US802133114 Oct 200520 Sep 2011Atrium Medical CorporationMethod of coating a folded medical device
US803436121 Dic 200611 Oct 2011Advanced Cardiovascular Systems, Inc.Stent coatings incorporating nanoparticles
US80424863 Jun 200825 Oct 2011Advanced Cardiovascular Systems, Inc.Stent spin coating apparatus
US809726812 Jun 200917 Ene 2012Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US810923022 Mar 20077 Feb 2012Advanced Cardiovascular Systems, Inc.Apparatus and method for coating and drying multiple stents
US812411929 Jul 200928 Feb 2012Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US819267819 Ago 20105 Jun 2012Advanced Cardiovascular Systems, Inc.Method of fabricating an implantable medical device with biaxially oriented polymers
US81927853 Ene 20075 Jun 2012Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US820253028 Nov 200519 Jun 2012Advanced Cardiovascular Systems, Inc.Biocompatible coatings for stents
US82114899 Dic 20083 Jul 2012Abbott Cardiovascular Systems, Inc.Methods for applying an application material to an implantable device
US826822811 Dic 200718 Sep 2012Abbott Cardiovascular Systems Inc.Method of fabricating stents from blow molded tubing
US830329627 Jul 20116 Nov 2012Abbott Cardiovascular Systems Inc.Polymer tube expansion apparatus to maximize fracture toughness
US83233293 May 20104 Dic 2012Advanced Cardiovascular Systems, Inc.Stents with enhanced fracture toughness
US83379376 Jun 200825 Dic 2012Abbott Cardiovascular Systems Inc.Stent spin coating method
US834935029 Jul 20098 Ene 2013Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US83615389 Dic 200829 Ene 2013Abbott LaboratoriesMethods for applying an application material to an implantable device
US836709112 Jun 20095 Feb 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US837012030 Abr 20105 Feb 2013Abbott Cardiovascular Systems Inc.Polymeric stents and method of manufacturing same
US843528614 Oct 20037 May 2013Medtronic Vascular, Inc.Stent with intermittent coating
US850107914 Sep 20096 Ago 2013Abbott Cardiovascular Systems Inc.Controlling crystalline morphology of a bioabsorbable stent
US85342233 Ene 201217 Sep 2013Advanced Cardiovascular Systems, Inc.System for coating a stent
US855144618 Sep 20078 Oct 2013Advanced Cardiovascular Systems, Inc.Poly(vinyl acetal) coatings for implantable medical devices
US864175019 Sep 20074 Feb 2014Lifeshield Sciences LlcStent design with sheath attachment members
US865808128 Jul 201025 Feb 2014Advanced Cardiovascular Systems, Inc.Methods of fabricating stents with enhanced fracture toughness
US865808228 Ago 201225 Feb 2014Abbott Cardiovascular Systems Inc.Method of fabricating stents from blow molded tubing
US86897294 Ene 20088 Abr 2014Abbott Cardiovascular Systems Inc.Apparatus for coating stents
US87155643 May 20126 May 2014Advanced Cardiovascular Systems, Inc.Method of fabricating an implantable medical device with biaxially oriented polymers
US871577118 Sep 20096 May 2014Abbott Cardiovascular Systems Inc.Coated stent and method of making the same
US882830528 Sep 20129 Sep 2014Abbott Cardiovascular Systems Inc.Tube expansion processes for semicrystalline polymers to maximize fracture toughness
US884607029 Jul 200830 Sep 2014Advanced Cardiovascular Systems, Inc.Biologically degradable compositions for medical applications
US88712366 Jun 201328 Oct 2014Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US887188327 Jul 201028 Oct 2014Abbott Cardiovascular Systems Inc.Biocompatible coating for implantable medical devices
US888317521 Nov 200611 Nov 2014Abbott Cardiovascular Systems Inc.Block copolymers of acrylates and methacrylates with fluoroalkenes
US88831864 Ene 201311 Nov 2014Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US890062012 Oct 20062 Dic 2014DePuy Synthes Products, LLCDrug-impregnated encasement
US892517717 Jul 20126 Ene 2015Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US896158418 Dic 200624 Feb 2015Abbott Cardiovascular Systems Inc.Composite stent with regioselective material
US896158826 Sep 200624 Feb 2015Advanced Cardiovascular Systems, Inc.Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US89867266 Jun 201324 Mar 2015Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US90288597 Jul 200612 May 2015Advanced Cardiovascular Systems, Inc.Phase-separated block copolymer coatings for implantable medical devices
US90382608 May 201426 May 2015Abbott Cardiovascular Systems Inc.Stent with radiopaque markers
US905044222 Jun 20109 Jun 2015Atrium Medical CorporationExpandable fluoropolymer device for delivery of therapeutic agents and method of making
US905615529 May 200716 Jun 2015Abbott Cardiovascular Systems Inc.Coatings having an elastic primer layer
US906700018 Nov 201330 Jun 2015Abbott Cardiovascular Systems Inc.End-capped poly(ester amide) copolymers
US907282026 Jun 20067 Jul 2015Advanced Cardiovascular Systems, Inc.Polymer composite stent with polymer particles
US908467115 Jul 201321 Jul 2015Advanced Cardiovascular Systems, Inc.Methods of forming a micronized peptide coated stent
US910169711 Abr 201411 Ago 2015Abbott Cardiovascular Systems Inc.Hyaluronic acid based copolymers
US911419819 Nov 200325 Ago 2015Advanced Cardiovascular Systems, Inc.Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US917373321 Ago 20063 Nov 2015Abbott Cardiovascular Systems Inc.Tracheobronchial implantable medical device and methods of use
US91739824 Ene 20133 Nov 2015Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US917516219 Sep 20073 Nov 2015Advanced Cardiovascular Systems, Inc.Methods for forming stent coatings comprising hydrophilic additives
US919878214 Abr 20141 Dic 2015Abbott Cardiovascular Systems Inc.Manufacturing process for polymeric stents
US91987854 Dic 20131 Dic 2015Abbott Cardiovascular Systems Inc.Crush recoverable polymer scaffolds
US92116824 Ene 201315 Dic 2015Abbott Cardiovascular Systems Inc.Controlling crystalline morphology of a bioabsorbable stent
US921623814 Abr 201422 Dic 2015Abbott Cardiovascular Systems Inc.Implantable medical device having reduced chance of late inflammatory response
US924803423 Ago 20052 Feb 2016Advanced Cardiovascular Systems, Inc.Controlled disintegrating implantable medical devices
US925934127 Feb 201316 Feb 2016Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US928309925 Ago 200415 Mar 2016Advanced Cardiovascular Systems, Inc.Stent-catheter assembly with a releasable connection for stent retention
US929557023 Feb 200529 Mar 2016Abbott Laboratories Vascular Enterprises LimitedCold-molding process for loading a stent onto a stent delivery system
US93395929 Abr 200717 May 2016Abbott Cardiovascular Systems Inc.Polymers of fluorinated monomers and hydrocarbon monomers
US935832522 Abr 20157 Jun 2016Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
US936449822 Jun 200914 Jun 2016Abbott Cardiovascular Systems Inc.Heparin prodrugs and drug delivery stents formed therefrom
US93645886 Jun 201414 Jun 2016Abbott Cardiovascular Systems Inc.Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US937544522 Jun 200928 Jun 2016Abbott Cardiovascular Systems Inc.Heparin prodrugs and drug delivery stents formed therefrom
US938168327 Dic 20125 Jul 2016DePuy Synthes Products, Inc.Films and methods of manufacture
US94461733 Oct 201420 Sep 2016Abbott Cardiovascular Systems Inc.Block copolymers of acrylates and methacrylates with fluoroalkenes
US95171499 Oct 201313 Dic 2016Abbott Cardiovascular Systems Inc.Biodegradable stent with enhanced fracture toughness
US952250321 Nov 201320 Dic 2016Abbott Cardiovascular Systems Inc.Methods of treatment with stents with enhanced fracture toughness
US953288831 Dic 20143 Ene 2017Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
US955492517 Abr 201431 Ene 2017Abbott Cardiovascular Systems Inc.Biodegradable polymeric stents
US956130927 May 20047 Feb 2017Advanced Cardiovascular Systems, Inc.Antifouling heparin coatings
US956135131 May 20067 Feb 2017Advanced Cardiovascular Systems, Inc.Drug delivery spiral coil construct
US957922524 Nov 201428 Feb 2017Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US95792601 Oct 201428 Feb 2017DePuy Synthes Products, Inc.Drug-impregnated encasement
US95805589 Jun 200828 Feb 2017Abbott Cardiovascular Systems Inc.Polymers containing siloxane monomers
US969411610 May 20164 Jul 2017Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
USRE457447 Nov 201313 Oct 2015Abbott Cardiovascular Systems Inc.Temperature controlled crimping
Clasificaciones
Clasificación internacionalA61F2/92, A61F2/00, A61L31/10, A61K47/48, A61L31/16, A61F2/88
Clasificación cooperativaA61K47/6957, A61F2/88, A61L31/10, A61L31/16, A61F2/92, A61F2250/0067, A61L2300/608
Clasificación europeaA61K47/48W26, A61L31/10, A61L31/16
Eventos legales
FechaCódigoEventoDescripción
9 Mar 2000AKDesignated states
Kind code of ref document: A1
Designated state(s): CA JP
9 Mar 2000ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
3 May 2000121Ep: the epo has been informed by wipo that ep was designated in this application
11 May 2000DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
25 Ene 2001ENPEntry into the national phase in:
Ref country code: CA
Ref document number: 2338788
Kind code of ref document: A
Format of ref document f/p: F
Ref document number: 2338788
Country of ref document: CA
28 Feb 2001ENPEntry into the national phase in:
Ref country code: JP
Ref document number: 2000 567257
Kind code of ref document: A
Format of ref document f/p: F
29 Mar 2001WWEWipo information: entry into national phase
Ref document number: 1999946670
Country of ref document: EP
1 Ago 2001WWPWipo information: published in national office
Ref document number: 1999946670
Country of ref document: EP
28 Feb 2002WWWWipo information: withdrawn in national office
Ref document number: 1999946670
Country of ref document: EP